NCT05823623View on ClinicalTrials.gov

Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 13, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2025

Conditions
Breast Cancer
Interventions
DRUG

Inetetamab

Patients with HER2-positive metastatic breast cancer after progression on trastuzumab are enrolled and receive treatment.

DRUG

Pyrotinib

Patients with HER2-positive metastatic breast cancer after progression on trastuzumab are enrolled and receive treatment.

DRUG

Oral Vinorelbine Tartrate

Patients with HER2-positive metastatic breast cancer after progression on trastuzumab are enrolled and receive treatment.

Trial Locations (1)

210029

RECRUITING

The First Affiliated Hospital with Nanjing Medical University, Nanjing

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER